Detalles de la búsqueda
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer;
154(6): 1043-1056, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37994647
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int;
44(1): 113-124, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789669
3.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int;
44(5): 1108-1125, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517286
4.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res;
54(4): 382-391, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37983642
5.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology;
101(4): 270-282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455517
6.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology;
101(10): 624-633, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307798
7.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology;
101(9): 542-552, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552968
8.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology;
101(5): 283-291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36657420
9.
Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
Hepatol Res;
2023 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38015179
10.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res;
53(8): 737-748, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37020416
11.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res;
53(10): 1031-1042, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306040
12.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol;
38(8): 1389-1397, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231943
13.
A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients.
Medicina (Kaunas);
59(12)2023 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38138202
14.
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Hepatology;
74(2): 656-666, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33706421
15.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology;
100(12): 645-654, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103846
16.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res;
52(5): 462-470, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080087
17.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res;
52(3): 308-316, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34799975
18.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatol Res;
52(3): 235-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861090
19.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res;
52(9): 773-783, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35633504
20.
Risk Factors for Nephrotoxicity due to Tacrolimus Therapy for Ulcerative Colitis.
Digestion;
103(5): 339-346, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35705006